


- (c) a sulfonylurea;  
(d) a biguanide; and  
(e) an alpha-glucosidase inhibitor.]



*B2* *1* *1* (Amended) A method as claimed in claim 1 including adding a pharmaceutical carrier to the therapeutically effective amount of the anti-diabetic agent [drug].

*B2* *1* (Amended) A composition for the treatment of diabetes mellitus comprising:

- (a) a therapeutic amount of an insulin sensitizer; and  
(b) a therapeutic amount of an anti-diabetic agent. [a drug selected from the group consisting of: an orally ingestible insulin; an injectible insulin; a sulfonylurea; a biguanide; and an alpha-glucosidase inhibitor.]

Please add the following claims:

*30* *20* *116* A method as claimed in claim 1, wherein the anti-diabetic agent is selected from the group consisting of:

- (a) an orally ingestible insulin;  
(b) an injectible insulin;  
(c) a sulfonylurea;  
(d) a biguanide; and  
(e) an alpha-glucosidase inhibitor.

*B3* *cont'd.* *2* *21* A composition as claimed in claim 1, wherein the anti-diabetic agent is selected from the group consisting of: an orally ingestible insulin; an injectible insulin; a sulfonylurea; a biguanide; and an alpha-glucosidase inhibitor.

*32* *2* A composition as claimed in claim 1, wherein the anti-diabetic agent is

insulin.

<sup>14</sup> 33. A composition as claimed in claim <sup>3</sup> 32, wherein the insulin is injectible insulin.

<sup>21</sup> 34. A method for the treatment of diabetes mellitus comprising administering to a person afflicted with diabetes mellitus a therapeutic amount of an insulin sensitizer with a therapeutic amount of an orally ingestible anti-diabetic agent, wherein

(1) the insulin sensitizer is selected from the group consisting of: BRL-49653, Pioglitazone HCL, Troglitazone, MC 555, ALRT 268, LGD 1069, Chromic Picolinate and V-411, and wherein

(2) the anti-diabetic agent is selected from the group consisting of: an orally ingestible insulin; an injectible insulin; a sulfonylurea; a biguanide; and an alpha-glucosidase inhibitor.

<sup>3</sup> Donald <sup>22</sup> 35. The method of claim <sup>21</sup> 34, wherein the insulin sensitizer is V-411.

<sup>23</sup> 36. The method of claim <sup>21</sup> 34, wherein the anti-diabetic agent is an orally ingestible anti-diabetic agent.

<sup>24</sup> 37. The method of claim <sup>22</sup> 36, wherein the anti-diabetic agent is a sulfonylurea.

<sup>24</sup> 38. The method of claim <sup>22</sup> 35 wherein the anti-diabetic agent is an orally ingestible insulin.